EMBO Molecular Medicine (Jun 2017)

A normal genetic variation modulates synaptic MMP‐9 protein levels and the severity of schizophrenia symptoms

  • Katarzyna Lepeta,
  • Katarzyna J Purzycka,
  • Katarzyna Pachulska‐Wieczorek,
  • Marina Mitjans,
  • Martin Begemann,
  • Behnam Vafadari,
  • Krystian Bijata,
  • Ryszard W Adamiak,
  • Hannelore Ehrenreich,
  • Magdalena Dziembowska,
  • Leszek Kaczmarek

DOI
https://doi.org/10.15252/emmm.201707723
Journal volume & issue
Vol. 9, no. 8
pp. 1100 – 1116

Abstract

Read online

Abstract Matrix metalloproteinase 9 (MMP‐9) has recently emerged as a molecule that contributes to pathological synaptic plasticity in schizophrenia, but explanation of the underlying mechanisms has been missing. In the present study, we performed a phenotype‐based genetic association study (PGAS) in > 1,000 schizophrenia patients from the Göttingen Research Association for Schizophrenia (GRAS) data collection and found an association between the MMP‐9 rs20544 C/T single‐nucleotide polymorphism (SNP) located in the 3′untranslated region (UTR) and the severity of a chronic delusional syndrome. In cultured neurons, the rs20544 SNP influenced synaptic MMP‐9 activity and the morphology of dendritic spines. We demonstrated that Fragile X mental retardation protein (FMRP) bound the MMP‐9 3′UTR. We also found dramatic changes in RNA structure folding and alterations in the affinity of FMRP for MMP‐9 RNA, depending on the SNP variant. Finally, we observed greater sensitivity to psychosis‐related locomotor hyperactivity in Mmp‐9 heterozygous mice. We propose a novel mechanism that involves MMP‐9‐dependent changes in dendritic spine morphology and the pathophysiology of schizophrenia, providing the first mechanistic insights into the way in which the single base change in the MMP‐9 gene (rs20544) influences gene function and results in phenotypic changes observed in schizophrenia patients.

Keywords